AzTrials
AzTrials

Solid Tumor, AdultPhase 1NCT03992326

Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors

A Phase 1 study testing TIL, Cyclophosphamide and Fludarabine in people with Solid Tumor, Adult, run by Centre Hospitalier Universitaire Vaudois at 1 site in Switzerland.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Single center, single arm phase Ib trial to test the feasibility and safety of Tumor- Infiltrating Lymphocyte-Adoptive Cell Therapy (TIL-ACT) combined with low-dose irradiation in patients with advanced or metastatic solid tumors. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Solid Tumor, Adult
What is being tested?
TIL, Cyclophosphamide and Fludarabine
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
6 participants
Where
1 siteSwitzerland
Study dates
1 Sep 2019to 5 Mar 2021
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with locally advanced (not radically treatable) or metastatic solid tumors with the below cancer types, who progressed after at least one standard therapy for advanced disease, or for whom such therapy was proven to be intolerable, or is considered inappropriate. Prior immunotherapy is allowed.
  • Breast cancer: irrespective of hormone receptor, Human epidermal growth factor receptor 2 (HER2) status or molecular subtype.
  • Non-small cell lung cancer (NSCLC): irrespective of histological or molecular subtypes.
  • Ovarian cancer: patients with high-grade serous ovarian cancer (HGSOC).
  • Colon cancer: irrespective of molecular subtype.
  • Other solid tumor: Patients with any other histology (any molecular subtype) with the exception of primary brain tumors, as well as cutaneous, mucosal, and ocular/uveal melanoma.
Show all 54Show fewer
  • Patients who have previously undergone tumor resection or biopsy and for whom pre-REP TILs are already available and adequate for further REP expansion. The following conditions have to be met:
  • The Manufacturing facility / sponsor representative confirms that adequate pre-REP material (in quantity and quality) is available to move to REP.
  • At least one lesion accessible to biopsy for translational research (TR) at baseline and D30, without putting the patient at unusual risk. Every effort should be made to obtain a fresh tumor biopsy upon enrolment, if previous collection of tissue is judged insufficient for study translational endpoints. The following exceptions are accepted for the baseline biopsy:
  • Tumor material was properly collected for all protocol translational endpoints during harvesting surgery or biopsy for the TIL production (pre-REP) and no intercurrent anticancer therapy has been administered since that surgery or last biopsy. If patient has been treated with any antitumor therapy that may have altered the tumor microenvironment at the estimation of the PI, a repeat biopsy should be performed.
  • Male or female age ≥ 18 to ≤ 70 years at the time of informed consent. Patients aged >70 will be evaluated by the investigator, and decision will be made according to patient's status, upon agreement with the PI.
  • Clinical performance status of Eastern Cooperative Oncology Group (ECOG) of 0 to 2.
  • Life expectancy of greater than 12 weeks.
  • Radiologically measurable disease (as per RECIST v1.1).
  • Modified RECIST should be used for mesothelioma.
  • Prostate Cancer Working Group 3 (PCWG3) criteria should be used for prostate cancer
  • Patients with brain metastases are eligible after discussion and agreement with the PI, provided there are no more than 3 residual metastases, that all metastases have been treated with stereotactic radiation therapy or gamma knife therapy and are asymptomatic. Lesions should be stable for at least 1 month, as determined by CT or MRI evaluation after treatment and should not require steroids.
  • Note: Patients presenting between three and five treated and inactive brain metastases can be considered for enrollment, after discussion and agreement with the PI.
  • Adequate viral serology defined by the following laboratory results obtained during screening period (within 17 days prior registration).
  • Seronegative for HIV infection (anti-HIV-1/-2)
  • Seronegative for hepatitis B infection (HBsAg, total anti-hepatitis B core antigen (HBc), anti-HBs). Exception is made in case of prior vaccination. Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen HBsAg test and a positive anti-HBc antibody test) are eligible, if Hepatitis B virus (HBV) DNA test is negative.
  • Seronegative for hepatitis C infection (anti-HCV): if a patient has positive anti-HCV antibody, a negative HCV RNA need to be obtained to register the patient.
  • Hematology
  • Absolute neutrophil count ≥ 1.0 x 10^9 cell/L without the support of granulocyte colony stimulating factor (G-CSF).
  • Platelet count ≥ 100 x10 ^9 cell/L
  • Hemoglobin ≥ 80 g/L. Subjects may be transfused to reach this cut-off.
  • Coagulation
  • International normalization ratio (INR) ≤1.5 times the upper limit of normal (x ULN) unless the subject is receiving anticoagulant therapy as long as INR/PT and partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants.
  • Exception: for patients with hepatocellular carcinoma (HCC), the INR may be up to 2.2, as long as the Child-Pugh score is A6 maximum.
  • PTT or activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless the subject is receiving anticoagulant therapy as long as INR/PT and PTT/aPTT is within therapeutic range of intended use of anticoagulants.
  • Chemistry:
  • Serum Alanine transaminase (ALT)/Aspartate aminotransferase (AST) ≤ to 3 x ULN i) Exception: ALT/AST considered related to liver metastasis ≤ to 5 x ULN ii) Exception: for patients with HCC serum ALT/AST ≤ to 5 x ULN
  • Total bilirubin ≤1.5 x ULN i) Exception: in patients with Gilbert's syndrome who must have a total bilirubin ≤2.5 x ULN ii) Exception: total bilirubin considered related to liver metastasis ≤3 x ULN iii) Exception: for patients with HCC total bilirubin ≤2.3 x ULN, as long as the Child-Pugh score is A6 maximum
  • Creatinine clearance by Cockcroft-Gault formula ≥ 40 ml/min
  • Adequate cardiovascular function, with documented left ventricular ejection fraction (LVEF) ≥ 45%. This parameter must be documented within 12 weeks before registration
  • Adequate respiratory function with forced expiratory volume in 1 second (FEV1) ≥ 50% predicted, forced vital capacity (FVC) ≥ than 50% predicted and diffusing capacity of lung for carbon monoxide (DLCO) ≥ than 50% predicted corrected. Patients with lung cancer or mesothelioma and values slightly under these limits (but >30% of predicted) can be enrolled after discussion and approval by the trial chair. These parameters must be documented within 12 weeks before registration
  • At the time the patient receives the NMA chemotherapy regimen (D-7):
  • ≥28 days must have elapsed from any chemotherapeutic cytotoxic drug
  • ≥28 days must have elapsed from bevacizumab, aflibercept and other anti-angiogenic antibodies
  • ≥28 days or 5 half-lives (whichever is shorter) must have elapsed from a non-cytotoxic drug including but not limited to trastuzumab, pertuzumab, and other molecular targeted therapy (such as tyrosine kinase inhibitors), etc… i) Note: In case of probable tumor flare upon stopping of the non-cytotoxic drug, the investigator may decide to shorten this delay, upon agreement of the trial chair, in a case-by-case approach.
  • ≥21 days must have elapsed from the last antibody therapy that could affect an anti-cancer immune response, including but not limited to anti-CTLA4, anti-Programmed cell death protein 1 (PD-1)), anti-Programmed death-ligand 1 (PD-L1), anti-Tumor Necrosis Factor Receptor Superfamily, member 4 (OX-40), or anti-Lymphocyte-activation gene 3 (LAG3) antibody therapy or their combination
  • Exceptions: denosumab and biphosphonates are permitted
  • Exceptions: androgen-deprivation therapy (ADT) for prostate cancer and hormonal therapy for breast cancer are permitted (and will be administered as SOC).
  • Patients' toxicities from previous therapies must have recovered to at least grade 1 according to NCI CTCAE v5.0, except for toxicities described below, as long as they do not put at risk the patient's condition and do not require systemic immunosuppressive steroids at immunosuppressive doses, including but not limited to:
  • Fatigue
  • Alopecia
  • Skin disorders
  • Stable neuropathy
  • Endocrinopathies requiring replacement treatment Note: For other medical conditions, or for any other toxicity with a higher grade but controlled by adequate treatment, prior discussion and agreement with the trial chair is mandatory.
  • Note: Patients may have undergone surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less.
  • For women of childbearing potential (WOCBP: sexually mature women who have not undergone a hysterectomy and/or bilateral oophorectomy, have not been naturally post-menopausal for at least 12 consecutive months or have a serum follicle-stimulating hormone (FSH) < 40 milli-international units per milliliter (mIU/ml):
  • Agreement to follow instructions for method(s) of contraception for the couple from screening until month 6 post start of NMA chemotherapy of the study.
  • Negative pregnancy test (urine or serum) during screening.
  • For men participating in the trial and their female partners: agreement to follow instructions for method(s) of contraception for the couple from screening until month 6 post start of NMA chemotherapy of the study.

Who cannot join

  • Patients with an active second malignancy, except for
  • non-melanoma skin cancer that has been apparently cured or successfully resected
  • carcinoma in situ as long as they have been adequately treated
  • Any malignancy that can be adequately managed expectantly without compromising prognosis, and after PI agreement..
  • Patients who have a history of malignancy are not considered to have an active malignancy if they have completed therapy since at least 2 years and are considered by their treating investigator to be at ≤ 30% risk for relapse.
  • Patients with known peritoneal metastases who have a recent history of intermittent bowel obstruction (even partial), unless such obstruction has been resolved. Agreement with the Trial Chair is mandatory.
Show all 22Show fewer
  • Patients with leptomeningeal carcinomatosis
  • History of idiopathic pulmonary fibrosis or evidence of active pneumonitis (any origin)
  • History of recent myocardial infarction or unstable angina, either within six months of enrolment
  • Documented Child-Pugh score of B or C for hepatocellular carcinoma patients with known underlying liver dysfunction
  • Active severe systemic infections within four weeks prior to beginning of NMA chemotherapy.
  • Patient requiring regular systemic immunosuppressive therapy (for example for organ transplantation, chronic rheumatologic disease); all immunosuppressive medications including but not limited to steroids, mycophenolate mofetil, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (TNF)-alpha agents must have been discontinued within the last two weeks prior to starting NMA chemotherapy.
  • Note: Use of inhaled or topical steroids or corticosteroid use for radiographic procedures is permitted
  • Note: The use of physiologic corticosteroid replacement therapy is permitted.
  • History of severe immediate hypersensitivity reaction to any of the agents used in this study.
  • History of immediate hypersensitivity reaction to aminoglycosides (e.g. gentamicin or streptomycin).
  • Women who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.
  • Subjects for whom there are concerns that they will not reliably comply with the requirements for contraception should not be enrolled into the study.
  • Any serious underlying medical condition that could interfere with study medication and potential adverse events.
  • Any mental or other impairment that may compromise compliance with the requirements of the study.
  • Patient participation in any other study currently receiving treatment. If the patient is in the follow-up period, he/she may be enrolled, as far as the elapsed time since the last previous treatment administration and the preparative regimen (NMA chemotherapy) is respected according to Inclusion Criteria n°15).
  • Participation in a research project using radiation sources exceeding an effective dose of 5 millisievert (mSv) with no direct benefit within the 12 last months.

Trial locations and contacts

1 site in 1 country.

Switzerland1 site

  • CHUV Oncology Department

    Lausanne, Canton of Vaud, 1011

Other trials in Switzerland

About this study

Official title: Phase Ib Study To Assess The Feasibility And Safety Of Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes In Advanced Solid Tumors

Single center, single arm phase Ib trial to test the feasibility and safety of Tumor- Infiltrating Lymphocyte-Adoptive Cell Therapy (TIL-ACT) combined with low-dose irradiation in patients with advanced or metastatic solid tumors. The trial is based on lymphodepleting chemotherapy followed by low dose irradiation (LDI), and then ACT utilizing ex vivo expanded TILs in combination with high dose IL-2 (optional, depending on patient's tolerance). LDI will be administered once to metastatic lesions using tomotherapy.

Read the detailed description

The objective of the trial is to define the feasibility and safety of TIL-ACT in combination with low-dose irradiation (LDI) in patients with advanced or metastatic solid tumors.

Study treatment will begin with intravenous (IV) non-myeloablative (NMA) lymphodepleting chemotherapy composed by fludarabine and cyclophosphamide. Both treatments will be started on the same day. Fludarabine will be administered for five days, and cyclophosphamide for two days. Low-dose irradiation (LDI) will be then administered once, to up to 20 measurable tumor lesions using tomotherapy.

TIL infusion will be performed intravenously followed by high dose IL-2 administration every eight hours, for a maximum of eight doses. Supportive care will be given as needed during the whole treatment period.

Patients achieving a stable disease, partial response or complete response after TIL-ACT treatment will then enter a follow-up period for 5 years.

Being tested
TIL, Cyclophosphamide, Fludarabine, Interleukin-2, Radiotherapy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TILOther

    Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes

  • CyclophosphamideDrug

    Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.

  • FludarabineDrug

    Fludarabine will be administered as an intravenous (IV) infusion for five days.

  • Interleukin-2Drug

    After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.

  • RadiotherapyOther

    Low-dose irradiation (1Gy) will be administered using tomotherapy to up to 20 measurable tumor lesions once before TIL infusion.

Study groups in NCT03992326
Study groupRoleWhat they receive
TIL-ACT + LDIExperimentalNon-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Low Dose Irradiation (LDI), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2).
Receives: Other: TIL; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Interleukin-2; Other: Radiotherapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Feasibility of TIL-ACT in combination with LDI - successful Rapid Expansion Protocol (REP): Number of patients for whom TIL cultures

    Number of patients for whom TIL cultures after REP achieve the required cell number and release criteria to start TIL-ACT infusion.

    Measured: Evaluated for each patient at day 0. After day 0 of the last patient, the number of patients with successful TIL-ACT infusion will be calculated.

  2. Feasibility of TIL-ACT in combination with LDI - successful infusion: Number of patients receiving a complete TIL-ACT infusion

    Number of patients receiving a complete TIL-ACT infusion (planned NMA chemotherapy, planned LDI and at least partial TIL infusion; no minimum IL-2 required)

    Measured: Evaluated for each patient at day 0, up to 60 mins after start of TIL-ACT infusion. At day 0 of the last patient, the number of patients with successful TIL-ACT infusion will be calculated.

  3. Toxicity of TIL-ACT and LDI

    Number of patients with adverse events as assessed by CTCAE version 5.0

    Measured: Treatment limiting toxicity (TLT) period: from chemotherapy start until Day30

Secondary outcomes (4)

  1. Disease control rate (DCR)

    Achievement of complete response, partial response or stable disease

    Measured: 1, 3, 6, 9, 12 months

  2. Objective response rate (ORR)

    Best overall response

    Measured: 1, 3, 6, 9, 12 months

  3. Progression free survival (PFS) for TIL-ACT

    Time from start of NMA chemotherapy until objective tumor progression (using RECIST criteria) or death if not documented progression.

    Measured: 5 years

  4. Overall survival (OS)

    Time from start of NMA chemotherapy until death

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jun 2019
  2. Study start1 Sep 2019
  3. Primary completion5 Mar 2021
  4. Study completion5 Mar 2021

Why it stopped: Internal competitive study that is open

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
6 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03992326
Sponsor's protocol ID
CHUV-DO-0012-SolTIL_2018
Status last verified
Mar 2021
First submitted
18 Jun 2019
Last updated
18 Mar 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing TIL, Cyclophosphamide and Fludarabine in people with Solid Tumor, Adult, run by Centre Hospitalier Universitaire Vaudois at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 54 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 18 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: Internal competitive study that is open). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Feasibility of TIL-ACT in combination with LDI - successful Rapid Expansion Protocol (REP): Number of patients for whom TIL cultures (time frame: Evaluated for each patient at day 0. After day 0 of the last patient, the number of patients with successful TIL-ACT infusion will be calculated.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03992326.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2021.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in